Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Assessment of the Cardiac Effects the Proteasome Inhibitor Bortezomib in Patients Undergoing Therapy for Multiple Myeloma

NCT02026505 is registered in ClinicalTrials.gov with Oregon Health and Science University as lead sponsor.

NCT NCT02026505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02026505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Assessment of the Cardiac Effects the Proteasome Inhibitor Bortezomib in Patients Undergoing Therapy for Multiple Myeloma
Lead sponsor
Oregon Health and Science University
Phase
Observational
Overall status
Completed
Start date
March 1, 2014
Completion date
March 1, 2019
Enrollment
11 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiotoxins, heart failure, systolic, multiple myeloma